Testosterone Therapy: Injectables, Topicals, HCG & Clomid — A Complete Guide

Testosterone: More Than a Number

Testosterone is the primary male sex hormone, but it does far more than drive libido. It influences energy, mood, cognition, bone density, muscle mass, fat distribution, red blood cell production, insulin sensitivity, and cardiovascular health. When levels decline — whether from age, illness, medication, or primary testicular failure — men can feel the difference long before a lab number explains it.

For decades, testosterone replacement therapy (TRT) has been clouded by myths: that it causes prostate cancer, that it triggers heart attacks, that any man with a "low" number needs treatment, and that any man with a "normal" number does not. Modern endocrinology has overturned each of these claims. This guide walks through what testosterone therapy actually is, how injectable and topical formulations compare, when HCG or Clomid are better choices, and what the safety evidence really shows.

A Brief History of Testosterone Research

The story of testosterone is older than most patients realize. In 1889, the French physiologist Charles-Édouard Brown-Séquard injected himself with extracts from animal testicles and reported renewed vigor — the first recorded attempt at hormone replacement. The science was crude, but the question was launched.

In 1935, three independent research groups — led by Ernst Laqueur, Adolf Butenandt, and Leopold Ružička — isolated, identified, and synthesized testosterone within months of one another. Butenandt and Ružička shared the Nobel Prize in Chemistry in 1939 for the work. For the first time, physicians had a pure hormone they could measure and prescribe.

Through the 1940s–1970s, testosterone was used widely but unevenly, often without rigorous diagnosis. The 1990s brought the modern era: validated radioimmunoassays for measuring serum testosterone, the introduction of transdermal patches and gels, and the recognition of "late-onset hypogonadism" as a legitimate clinical entity.

The 2000s and 2010s were turbulent. Two flawed studies in 2010 and 2013 suggested TRT increased cardiovascular events, prompting an FDA warning. But subsequent reanalysis exposed serious methodological errors, and the landmark TRAVERSE trial (2023) — a randomized, placebo-controlled study of more than 5,200 men with cardiovascular risk factors — found no increase in major cardiovascular events with testosterone therapy. The pendulum has now swung back toward evidence-based, individualized prescribing.

There Is No Magic Number

One of the most important things to understand about testosterone is that no single lab value defines who needs treatment. Reference ranges in North American labs typically span roughly 250–900 ng/dL for total testosterone, but those numbers come from population averages, not from biology that says "below this, you are sick."

Two men with identical testosterone levels can feel completely different. A 35-year-old at 380 ng/dL may have profound fatigue, low libido, brain fog, and erectile dysfunction. A 70-year-old at the same number may feel perfectly well. Free testosterone, sex hormone binding globulin (SHBG), albumin, estradiol, LH, FSH, prolactin, and the patient's symptoms all shape the clinical picture.

The right approach is symptoms plus labs, interpreted together. Diagnosis of testosterone deficiency should never be made on a number alone, and it should never be dismissed on a number alone either. A thoughtful clinician treats the patient, not the printout.

Injectable Testosterone

Injectable testosterone — most commonly testosterone cypionate or testosterone enanthate in North America — remains the gold standard for many men. It is delivered intramuscularly into the shoulder, thigh, or gluteal region.

Advantages: - Highly effective at restoring serum levels - Inexpensive and widely available - Flexible dosing tailored to the individual by the prescribing clinician - Can be self-administered after proper training

Trade-offs: - Peaks and troughs in blood levels if dosed infrequently — modern practice favors smaller, more frequent doses to keep levels steady - Suppresses the brain's signal to the testicles, leading to testicular atrophy and infertility if used alone - Requires periodic monitoring of hematocrit, estradiol, PSA, and lipids

Topical Testosterone

Topical testosterone comes as a gel, cream, or solution applied daily to the shoulders, upper arms, or abdomen. It produces smoother, more physiologic daily levels than infrequent injections and avoids needles entirely.

Advantages: - Steady daily levels mimicking natural diurnal rhythm - No injections - Easy to titrate up or down

Trade-offs: - Risk of skin transfer to women and children — a real concern in households with close contact - Absorption varies between individuals; some men simply do not absorb enough through the skin - Daily application required without fail - Generally more expensive than injectable cypionate

For men who travel frequently, dislike needles, or want the most physiologic profile, a high-quality compounded cream applied to a clean, dry area is often the best choice.

HCG and Clomid: When the Better Answer Isn't Testosterone

Standard TRT shuts down the hypothalamic-pituitary-gonadal axis. The brain stops sending LH and FSH to the testicles, which stop producing their own testosterone and stop making sperm. For older men who are done having children, this is usually acceptable. For younger men — or any man who wants to preserve fertility — there are better options.

Human Chorionic Gonadotropin (HCG)

HCG mimics LH, the pituitary hormone that tells the testicles to produce testosterone and maintain sperm production. It can be used:

• Alongside TRT to preserve testicular size and fertility while a man is on testosterone
• As a standalone treatment in men with secondary hypogonadism (a pituitary problem rather than a testicular one) who want to raise their own testosterone production
• As part of post-cycle recovery for men coming off TRT or anabolic steroids

Dosing is individualized by the prescribing clinician and administered two or three times per week. It is well tolerated and does not require needles any larger than an insulin syringe.

Clomiphene (Clomid) and Enclomiphene

Clomiphene is a selective estrogen receptor modulator (SERM) that blocks estrogen feedback at the pituitary, causing the brain to release more LH and FSH. The result: the testicles produce more of the man's own testosterone, and sperm production is preserved or even improved.

Indications for Clomid or enclomiphene: - Younger men with secondary hypogonadism who want to maintain fertility - Men trying to conceive in the next year or two - Men who prefer an oral therapy over injections or gels - Men with borderline low testosterone who respond well to a pituitary nudge

Enclomiphene, the purified isomer, has fewer mood-related side effects than racemic clomiphene and is increasingly preferred. Either way, this is one of the most underused tools in men's health — many men prescribed standard TRT could have been managed with Clomid first.

Testosterone and Prostate Cancer: Setting the Record Straight

For sixty years, testosterone was thought to "feed" prostate cancer based on a single 1941 paper by Charles Huggins. That belief is now obsolete.

The saturation model, validated repeatedly since 2006 by Dr. Abraham Morgentaler and others, demonstrates that prostate tissue's androgen receptors are fully saturated at very low testosterone levels. Adding more testosterone above that threshold does not stimulate additional prostate growth. Large modern studies — including data from men with treated prostate cancer — show that TRT does not cause prostate cancer and does not accelerate its growth when properly monitored.

This does not mean monitoring is optional. PSA and digital rectal exam at baseline, three months, and annually thereafter remain standard. But the blanket prohibition of testosterone in men with prostate concerns is no longer evidence-based.

Testosterone and Heart Disease: What TRAVERSE Showed

The 2013–2014 cardiovascular scare was based on two studies with significant methodological problems, including miscoded data and a population that did not match the conclusion. The TRAVERSE trial (NEJM, 2023) — designed specifically by the FDA to settle the question — randomized 5,246 middle-aged and older men with cardiovascular risk factors to testosterone gel or placebo and followed them for an average of 33 months.

The result: no increase in heart attacks, strokes, or cardiovascular death.

Modest increases in atrial fibrillation, pulmonary embolism, and acute kidney injury were observed and warrant attention, but the central cardiovascular safety question has been answered. When testosterone is appropriately prescribed and properly monitored, it is a safe therapy for the cardiovascular system.

Safe Monitoring: The Non-Negotiables

Whether a man is on injectable, topical, HCG, or Clomid, structured follow-up is what makes therapy safe:

• Baseline labs: total and free testosterone, SHBG, estradiol, LH, FSH, prolactin, PSA, CBC, comprehensive metabolic panel, lipid panel
• Repeat labs at 6–12 weeks after starting or adjusting therapy, then every 6–12 months
• Hematocrit watch: testosterone can raise red blood cell count; values above 54% may require dose reduction or therapeutic phlebotomy
• Estradiol balance: too low impairs bone, mood, and libido; too high causes water retention and breast tenderness
• PSA tracking with prompt urology referral for any concerning rise
• Symptom review: energy, mood, libido, sleep, body composition, sexual function

Who Is a Candidate?

Men who may benefit from a testosterone evaluation include those experiencing persistent fatigue, low libido, erectile difficulty, loss of morning erections, depressed mood, brain fog, loss of muscle mass, increased abdominal fat, poor recovery from exercise, or unexplained anemia. None of these symptoms alone diagnose hypogonadism, but together with appropriate labs they tell a story.

Men who are actively trying to father children should generally start with HCG or Clomid rather than standard TRT. Men with untreated severe sleep apnea, uncontrolled heart failure, hematocrit above 54%, or active prostate or breast cancer require careful evaluation before therapy.

The Bottom Line

Testosterone therapy in 2026 is a precision treatment, not a one-size-fits-all prescription. There is no magic number that triggers it and no single formulation that suits every man. Injectable testosterone, topical preparations, HCG, and Clomid all have their place — and the right answer depends on a man's symptoms, goals, fertility plans, and overall health.

The fears of the past — prostate cancer, heart attacks, "unnatural" hormones — are not supported by the modern evidence. What the evidence does support is careful diagnosis, individualized prescribing, and consistent monitoring. That is the standard at ReGenesis: treat the man, not the number, and never stop watching the safety signals.

If you are wondering whether your symptoms might be related to testosterone, the next step is a comprehensive assessment with a clinician who understands the full toolkit.

Ready to Take the Next Step?

Book a confidential assessment with a ReGenesis clinician.

Call 587.635.3414